Why C5 Inhibition Leaves a Hemolysis Gap in PNH

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal disorder in which somatic mutations in the PIGA gene cause red blood cells to lack GPI-anchored complement regulators CD55 and CD59, leaving them catastrophically vulnerable to complement attack. C5 inhibitors — eculizumab and ravulizumab — transformed PNH management by blocking the terminal complement pathway and preventing intravascular hemolysis. Yet a clinically meaningful proportion of patients on C5 inhibitor therapy continue to experience residual anemia, fatigue, and transfusion dependence. The reason is mechanistically straightforward: C5 inhibitors act downstream of C3, so they do not prevent C3b and iC3b from opsonising PNH red blood cells and directing them to destruction by macrophages in the spleen and liver — a process called extravascular hemolysis (EVH).

The clinical consequence of EVH under C5 inhibition is a patient population that is partially treated: intravascular hemolysis is controlled, but C3-mediated red cell destruction continues. Haemoglobin levels often remain suppressed, and patients require ongoing transfusions despite being on a complement inhibitor. This unmet need — visible in real-world registries and confirmed in clinical sub-analyses — is the precise gap that proximal complement inhibitors targeting Factor B, Factor D, and C3 itself are designed to fill. According to data published in peer-reviewed haematology journals and reviewed by the New England Journal of Medicine, the magnitude of residual EVH varies considerably across patients, making biomarker-guided patient selection an active area of clinical and commercial interest.

Factor B as a Proximal Target: Mechanism and Therapeutic Logic

Factor B is an indispensable serine protease in the complement alternative pathway: without it, the amplification loop that drives the majority of complement activation in PNH cannot function. The alternative pathway is continuously activated at low levels through spontaneous C3 hydrolysis — a process called “tick-over.” In healthy individuals, surface-bound regulatory proteins rapidly displace and inactivate C3b. In PNH red cells, the absence of CD55 (which accelerates C3 convertase decay) and CD59 (which blocks membrane attack complex formation) means that every cycle of tick-over can initiate progressive complement deposition.

Factor B binds to surface-deposited C3b to form the proconvertase C3bB. Factor D then cleaves Factor B within this complex, releasing the Ba fragment and generating the active C3 convertase C3bBb. This convertase cleaves additional C3 molecules, depositing more C3b in an exponential amplification loop — and also cleaving C5 to initiate the terminal pathway. Blocking Factor B therefore simultaneously prevents C3 amplification (halting EVH) and prevents C5 cleavage (halting intravascular hemolysis). This dual action is the core mechanistic argument for Factor B inhibition as a superior monotherapy target compared with C5 inhibition alone.

The therapeutic logic of targeting Factor B is reinforced by the biology of the alternative pathway amplification loop. Estimates from complement pharmacology research suggest that the alternative pathway accounts for the majority of total complement activation in PNH, even when classical or lectin pathway triggers initiate the response, because the amplification loop dramatically amplifies any upstream signal. Blocking Factor B therefore truncates complement activation at its most consequential amplification node. This is distinct from Factor D inhibition, which targets the enzyme that activates Factor B — a mechanistically adjacent but structurally and commercially different approach, as exemplified by danicopan (ALXN2040, AstraZeneca/Alexion), which is positioned as an add-on to anti-C5 therapy rather than as a standalone monotherapy.

Iptacopan’s Clinical Evidence and What the Trial Data Show

Iptacopan (LNP023, Novartis) is an oral, once-daily, small-molecule inhibitor of Factor B that received its first regulatory approval for PNH in 2023, making it the first oral complement inhibitor approved as a monotherapy for this disease. The pivotal evidence base rests on two Phase 3 trials: APPLY-PNH, which enrolled patients with PNH who had residual anaemia despite anti-C5 therapy, and APPOINT-PNH, which enrolled complement inhibitor-naïve patients.

“More than 80% of patients switching to iptacopan from anti-C5 therapy achieved a haemoglobin increase of at least 2 g/dL — and 69% achieved transfusion independence.”

In APPLY-PNH, patients who had been on eculizumab or ravulizumab and still had haemoglobin below 10 g/dL were randomised to switch to iptacopan monotherapy or continue their anti-C5 regimen. The results were striking: more than 80% of patients in the iptacopan arm achieved a sustained haemoglobin increase of at least 2 g/dL from baseline, compared with none in the anti-C5 continuation arm meeting this threshold. Transfusion independence was achieved by 69% of iptacopan-treated patients. These data, published in peer-reviewed haematology literature and assessed by regulatory agencies including the European Medicines Agency and the FDA, established iptacopan as a clinically superior option for this sub-population. In APPOINT-PNH, treatment-naïve patients on iptacopan also showed robust haematological responses, supporting its use as a first-line oral monotherapy.

The safety profile of iptacopan in these trials was consistent with its mechanism. Because Factor B inhibition suppresses the alternative pathway amplification loop — a key defence against encapsulated bacteria — patients require vaccination against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae before initiating therapy, mirroring the infection risk management established for C5 inhibitors. Iptacopan’s oral bioavailability and once-daily dosing represent a substantial quality-of-life improvement over the two-weekly or eight-weekly intravenous infusions required for eculizumab and ravulizumab respectively — a differentiation point that is increasingly prominent in prescriber and payer discussions.

The Oral Complement Pipeline: Factor D, Factor B, and C3-Level Competitors

Iptacopan’s approval has not closed the competitive field — it has opened it. The commercial validation of oral complement inhibition in PNH has accelerated investment across three mechanistic categories, each with distinct clinical positioning, IP profiles, and commercial strategies.

Factor D Inhibitors: Add-On Strategy

Danicopan (ALXN2040, AstraZeneca/Alexion) is the most advanced oral Factor D inhibitor in PNH. Factor D is the rate-limiting enzyme that cleaves Factor B within the C3bB proconvertase, so its inhibition also prevents C3 convertase assembly — but via a different molecular target and binding site from Factor B inhibitors. Danicopan’s regulatory strategy has been built around add-on use in patients on eculizumab or ravulizumab who have clinically significant EVH, rather than as a monotherapy replacement. This positions it as complementary to the existing C5 inhibitor market rather than disruptive to it, a commercially pragmatic choice given AstraZeneca/Alexion’s dominant position in anti-C5 therapies. Clinical data for danicopan as an add-on showed meaningful reductions in lactate dehydrogenase and improvements in haemoglobin in patients with breakthrough EVH on anti-C5 therapy, as reviewed by the FDA in its approval assessment.

C3-Level Inhibitors: Subcutaneous Proximal Blockade

Pegcetacoplan (Empaveli/Aspaveli, Apellis Pharmaceuticals) is a subcutaneous C3 inhibitor — not an oral agent, but a proximal complement blocker that also addresses EVH. By binding C3 and C3b directly, pegcetacoplan prevents all downstream complement activation regardless of the initiating pathway. Its twice-weekly subcutaneous self-injection represents a middle ground between the convenience of oral therapy and the potency of complete complement suppression. Clinical data in PNH showed haemoglobin improvements and transfusion independence rates broadly comparable to those seen with iptacopan in similar patient populations, establishing a competitive benchmark for proximal inhibition outcomes.

Emerging Oral Factor B Programs

Beyond iptacopan, multiple earlier-stage oral Factor B inhibitor programs are in clinical or late-preclinical development for PNH and other complement-mediated diseases including IgA nephropathy, C3 glomerulopathy, and geographic atrophy. These programs are exploring differentiated chemical scaffolds — distinct from iptacopan’s pyrrolidine-based Factor B binding motif — to achieve freedom-to-operate and potentially improved pharmacokinetic or selectivity profiles. The competitive pressure to develop next-generation oral Factor B inhibitors is significant: PNH is a validated proof-of-concept indication, and the same mechanism is being pursued across a broadening range of complement-driven diseases, as documented in clinical trial registries monitored by the WHO International Clinical Trials Registry Platform.

Patent Landscape and IP Strategy for Oral Alternative Pathway Inhibitors

The intellectual property landscape for oral complement alternative pathway inhibitors has become one of the most actively contested areas in rare disease drug IP, with patent filings intensifying significantly from 2018 onwards as clinical proof-of-concept data began to emerge. Understanding the structure of this IP landscape is essential for any organisation seeking to develop, licence, or commercialise oral complement inhibitors for PNH or adjacent indications.

Novartis holds core composition-of-matter patents on iptacopan covering its pyrrolidine-based Factor B binding scaffold — the foundational IP that protects the molecule itself and its closest chemical analogues. Beyond the core scaffold, Novartis and its competitors have filed patents covering: specific crystalline forms and polymorphs (relevant to formulation and manufacturing exclusivity); prodrug derivatives; specific dosing regimens and combination therapies; biomarker-based patient selection methods (identifying which PNH patients are most likely to benefit from proximal complement inhibition); and use patents in indications beyond PNH, including IgA nephropathy, C3 glomerulopathy, and atypical haemolytic uraemic syndrome.

Competitors developing next-generation oral Factor B inhibitors face a layered freedom-to-operate challenge. The core iptacopan scaffold is protected, but Factor B has multiple druggable binding sites — the active site serine, the S1 specificity pocket, the exosite involved in C3b binding — and alternative scaffolds engaging these sites differently may achieve both mechanistic differentiation and IP freedom. Several academic groups and biotechnology companies have published preclinical data on structurally distinct Factor B inhibitors, and patent applications from these programs are visible in global IP databases monitored through platforms such as PatSnap‘s innovation intelligence platform, which aggregates filings from the European Patent Office, USPTO, WIPO, and national patent offices across more than 120 countries.

The combination therapy IP space is particularly active. As the PNH treatment paradigm evolves toward combinations — for example, oral Factor B inhibition plus an anti-C5 agent for patients with breakthrough intravascular hemolysis, or oral Factor B inhibition plus an anti-complement regulatory protein for patients with specific complement genetic variants — method-of-treatment patents covering these combinations are being filed aggressively. These combination patents can extend effective market exclusivity well beyond the expiry of core composition-of-matter patents, making them strategically important assets for both originators and challengers. IP teams and R&D leaders in this space need real-time visibility into competitor filings to anticipate freedom-to-operate risks and identify white-space opportunities before they close.

Regulatory data exclusivity adds a further layer of protection beyond patents. In the United States, iptacopan benefits from orphan drug designation for PNH, conferring seven years of market exclusivity from approval. In the European Union, orphan designation provides ten years of market exclusivity. These exclusivity periods mean that even a generic or biosimilar developer who successfully circumvents the patent estate would face regulatory barriers to market entry until the orphan exclusivity expires. For competitors developing differentiated oral Factor B inhibitors — rather than generic copies — the relevant competitive window is defined by clinical differentiation and IP position rather than by regulatory exclusivity alone.